{"nctId":"NCT01233258","briefTitle":"A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A","startDateStruct":{"date":"2011-01"},"conditions":["Hemophilia A"],"count":80,"armGroups":[{"label":"Arm 1: rFVIII on demand first CS/EP then CS/ADJ","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) on demand"]},{"label":"Arm 2: rFVIII on demand first CS/ADJ then CS/EP","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) on demand"]},{"label":"Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) prophylaxis low-dose"]},{"label":"Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) prophylaxis low-dose"]},{"label":"Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) prophylaxis high-dose"]},{"label":"Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP","type":"EXPERIMENTAL","interventionNames":["Biological: rFVIII (BAY81-8973) prophylaxis high-dose"]}],"interventions":[{"name":"rFVIII (BAY81-8973) on demand","otherNames":[]},{"name":"rFVIII (BAY81-8973) prophylaxis low-dose","otherNames":[]},{"name":"rFVIII (BAY81-8973) prophylaxis high-dose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male, aged 12 to 65 years\n* Severe hemophilia A\n* History of more than 150 exposure days (ED) with clotting factor concentrates\n* Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years\n* No current Factor VIII inhibitor or history of inhibitor\n* Willing to use electronic patient diary\n\nExclusion Criteria:\n\n* Presence of another bleeding disease that is different from hemophilia A\n* Thrombocytopenia\n* Abnormal renal function\n* Presence of active liver disease\n* Known hypersensitivity to FVIII","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Number of All Bleeds","description":"The annualized number of bleeds experienced by participants","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":"24.6"},{"groupId":"OG001","value":"4.9","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of All Bleeds During CS/EP Period","description":"The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/EP","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","spread":"24.3"},{"groupId":"OG001","value":"5.1","spread":"8.0"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of All Bleeds During CS/ADJ Period","description":"The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/ADJ","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":"25.1"},{"groupId":"OG001","value":"4.8","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Bleeds Per Participant Controlled With â‰¤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)","description":"The percentage of bleeds per participant on on-demand treatment that stopped after two or fewer injections","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Bleeds During Treatment","description":"The number of bleeds experienced by each participant","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Inhibitory Antibody Formation","description":"A test to ensure that participants have not developed antibodies that will interfere with the action of rFVIII (BAY81-8973)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":80},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Influenza","Insomnia"]}}}